Difference between revisions of "Part:BBa K1694003"

Revision as of 19:43, 17 September 2015

Single-chain variable fragment (Anti-VEGF)

scFv(single-chain variable fragment) is a fusion protein that consist of variable region of heavy chain(VH) and light chain(VL) of antibody, and connected by a short linker. Here we use the amino acid sequence of GGSSRSSSSGGGGSGGGG as a linker to connect VH and VL.

Features of scFv：
1.Specificity：Though remove of the constant regions and add a linker, scFv still maintain the specificity of the original immunoglobulin.
2.Convenient：ScFv is smaller than the entire antibody, so that the loading of production to E.coli could become lower.

VEGF (Vascular endothelial growth factor), a protein that can stimulates vasculogenesis and angiogenesis. Some cancers can overexpress VEGF, which will cause some vascular disease. Drug bevacizumab can inhibit VEGF and control or slow those diseases.
VEGF is a sub-family of growth factors, which comprises：VEGF-A, placenta growth factor (PGF), VEGF-B, VEGF-C and VEGF-D.
There are three types of VEGF receptors on the cell surface, and VEGFR-2 is one type of receptor which can mediate almost all of the known cellular responses to VEGF. Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A). VEGF-A stimulates angiogenesis in a variety of diseases, especially in cancer.
Mechanism：
When VEGF-A binds to VEGFR-2, it causes two VEGFR-2 to combine to form a dimer. This allows for signaling molecules enter to the cell to bind to the receptor and become activated. Then start the angiogenesis.
Bevacizumab can bind with VEGF released from tumor cell, block VEGFR to inhibit tumor angiogenesis, thereby cutting off the tumor's supplies, to prevent tumor growth goal.

Sequence and Features